BimekizumabAn Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Sponsor:

UCB Biopharma SRL

Code:

NCT06668181

Conditions

Enthesitis-related Arthritis

Juvenile Psoriatic Arthritis

Eligibility Criteria

Sex: All

Age: 2 - 18

Healthy Volunteers: Not accepted

Interventions

Bimekizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-27. This information was provided to ClinicalTrials.gov by UCB Biopharma SRL on 2026-07-17.